Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2012 - 2025)

Ani Pharmaceuticals has disclosed Preferred Stock Liabilities across 6 years of filings, most recently posting $24.8 million for Q2 2025.

• Preferred Stock Liabilities for Q2 2025 came in at $24.8 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2025 was $24.8 million (changed 0.0% YoY), and the FY2024 annual result was $24.8 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $24.8 million for Q2 2025 at Ani Pharmaceuticals, roughly flat from $24.8 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $24.8 million in Q4 2021 to a low of $24.8 million in Q4 2021.
• The 5-year median for Preferred Stock Liabilities is $24.8 million (2021), against an average of $24.8 million.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Ani Pharmaceuticals' Preferred Stock Liabilities stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
• The last three Preferred Stock Liabilities figures came in at $24.8 million (Q2 2025), $24.8 million (Q1 2025), and $24.8 million (Q4 2024), per Business Quant data.